Guidelines (2008) for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the United Kingdom

Journal of Antimicrobial Chemotherapy

Volumn 63, Issue 5, 2009, Pages 849-861

  Gould, F Kate ^a   Brindle, Richard ^b   Chadwick, Paul R ^c   Fraise, Adam P ^d   Hill, Simon ^e   Nathwani, Dilip ^f   Ridgway, Geoff L ^g   Spry, Michael J ^a   Warren, Rod E ^h  

^a FREEMAN HOSPITAL   (United Kingdom)

^b QUEEN ALEXANDRA HOSPITAL   (United Kingdom)

^c HOPE HOSPITAL   (United Kingdom)

^d CITY HOSPITAL   (United Kingdom)

^e POOLE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^f UNIVERSITY OF DUNDEE   (United Kingdom)

^g Department of Health ^*  (United Kingdom)

^h ROYAL SHREWSBURY HOSPITAL   (United Kingdom)

Author keywords

Evidence based guidelines; Meticillin; New antistaphylococcal agents; UK; Update

Indexed keywords

ANTIBIOTIC AGENT; CLINDAMYCIN; COTRIMOXAZOLE; DAPTOMYCIN; DOXYCYCLINE; FUSIDATE SODIUM; FUSIDIC ACID; GENTAMICIN; LINEZOLID; MACROLIDE; PENICILLIN G; POLYPEPTIDE ANTIBIOTIC AGENT; PSEUDOMONIC ACID; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RETAPAMULIN; RIFAMPICIN; TETRACYCLINE; TIGECYCLINE; VANCOMYCIN;

ANEMIA; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; BACTEREMIA; BACTERIAL PNEUMONIA; BONE INFECTION; BONE MARROW SUPPRESSION; CENTRAL NERVOUS SYSTEM INFECTION; CEREBRAL BLINDNESS; CLINICAL PROTOCOL; CLINICAL TRIAL; DIARRHEA; DRUG BIOAVAILABILITY; DRUG CHOICE; DRUG EFFICACY; DRUG EXCRETION; DRUG TISSUE LEVEL; DRUG WITHDRAWAL; ENDOCARDITIS; ENZYME BLOOD LEVEL; EVIDENCE BASED PRACTICE; EYE INFECTION; HUMAN; IMPETIGO; INFECTIOUS ARTHRITIS; JAUNDICE; LOW DRUG DOSE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MONOTHERAPY; MUSCLE NECROSIS; NAUSEA; NEPHROTOXICITY; OSTEOMYELITIS; PERIPHERAL NEUROPATHY; PNEUMONIA; PRACTICE GUIDELINE; PROTEIN BLOOD LEVEL; RESPIRATORY TRACT INFECTION; REVIEW; SIDE EFFECT; SKIN INFECTION; SOFT TISSUE INFECTION; STEVENS JOHNSON SYNDROME; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE; UNITED KINGDOM; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION;

ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; CARRIER STATE; GREAT BRITAIN; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCAL INFECTIONS;

EID: 64649090999     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp065     Document Type: Review

References (132)

1. Hayward A, Knott F, Petersen IS et al. Increasing hospitalizations and general practice prescriptions for community-onset staphylococcal disease, England. Emerg Infect Dis 2008; 14: 720-6.
2. Combined Working Party of the Hospital Infection Society and British Society for Antimicrobial Chemotherapy. Guidelines for the control of epidemic methicillin-resistant Staphylococcus aureus. J Hosp Infect 1986; 7: 193-201.
3. Combined Working Party of the Hospital Infection Society and British Society for Antimicrobial Chemotherapy. Revised guidelines for the control of epidemic methicillin-resistant Staphylococcus aureus. J Hosp Infect 1990; 16: 351-77.
4. Combined Working Party of the British Society for Antimicrobial Chemotherapy, the Hospital Infection Society, the Infection Control Nurses Association. Revised guidelines for the control of methicillin-resistant Staphylococcus aureus infection in hospitals. J Hosp Infect 1998; 39: 253-90.
5. Gemmell CG, Edwards DI, Fraise AP et al. Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK. J Antimicrob Chemother 2006; 57: 589-608.
6. Nathwani D, Morgan M, Masterton R et al. Guidelines for UK practice for the diagnosis and management of MRSA infections presenting in the community. J Antimicrob Chemother 2008; 61: 976-94.
7. Scottish Medicines Consortium. Scottish Medicines Consortium: Submission Process. 2008. http://www.scottishmedicines.org.uk/smc/ controller?p_service=Content.show&p_applic=CCC&pContentID= 22&p_service=Content.show (23 December 2008, date last accessed).
8. Mangram AJ, Horan TC, Pearson ML et al. Guideline for prevention of surgical site infection, 1999. Infect Control Hosp Epidemiol 1999; 20: 247-78.
9. Leibovici L, Paul M. Comment on: Guidelines for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the UK. J Antimicrob Chemother 2006; 58: 220.
10. Warren J. Practice guidelines for the treatment of uncomplicated cystitis. Curr Urol Rep 2001; 2: 326-9.
11. Gupta K, Hooton T, Stamm SE. Increasing antimicrobial resistance and the management of community-acquired urinary tract infections. Ann Intern Med 2001; 135: 41-50.
12. Salgado CD, Farr BM, Calfee DP. Community-acquired methicillin-resistant Staphylococcus aureus: A meta-analysis of prevalence and risk factors. Clin Infect Dis 2003; 36: 131-9.
13. Tacconelli E, Venkataraman I, De Girolami PC et al. Methicillin-resistant Staphylococcus aureus bacteraemia diagnosed at hospital admission: Distinguishing between community-acquired versus healthcare-associated strains. J Antimicrob Chemother 2004; 53 474-9.
14. Calfee DP, Durbin LJ, Germanson TP et al. Spread of methicillin-resistant Staphylococcus aureus (MRSA) among household contacts of individuals with nosocomially acquired MRSA. Infect Control Hosp Epidemiol 2003; 24: 422-6.
15. Jernigan JA, Pullen AL, Flowers L et al. Prevalence and risk factors for colonization with methicillin-resistant Staphylococcus aureus at the time of hospital admission. Infect Control Hosp Epidemiol 2003; 24: 409-14.
16. Baba T, Takeuchi F, Kuroda M et al. Genome and virulence determinants of high virulence community-acquired MRSA. Lancet 2002; 359: 1819-27.
17. Vandenesch F, Naimi T, Enright MC et al. Community-acquired methicillin-resistant Staphylococcus aureus carrying Panton-Valentine leukocidin genes: Worldwide emergence. Emerg Infect Dis 2003; 9: 978-84.
18. Said-Salim B, Mathema B, Kreiswirth BN. Community-acquired methicillin-resistant Staphylococcus aureus: An emerging pathogen. Infect Control Hosp Epidemiol 2003; 24: 451-5.
19. Martinez-Aguilar G, Avalos-Mishaan A, Hulten K et al. Community-acquired methicillin-resistant and methicillin-susceptible Staphylococcus aureus musculoskeletal infections in children. Pediatr Infect Dis J 2004; 23: 701-6.
20. Lewis D, Campbell R, Cookson B et al. for the PVL sub-group of the Steering Group on Healthcare Associated Infections. Guidance on the Diagnosis and Management of PVL-Associated Staphylococcus aureus Infections (PVL-SA) in England. Department of Health, 2006. http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1218699411960 (23 January 2008, date last accessed).
21. Boyce JM. Methicillin-resistant Staphylococcus aureus. Detection, epidemiology, and control measures. Infect Dis Clin North Am 1989; 3: 901-13.
22. Schentag JJ, Hyatt J, Carr J et al. Genesis of methicillin-resistant Staphylococcus aureus (MRSA). How treatment of MRSA infections has selected for vancomycin-resistant Enterococcus faecium and the importance of antibiotic management and infection control. Clin Infect Dis 1998; 26: 1204-14.
23. Shlaes DM, Gerding DN, John JF et al. Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: Guidelines for the prevention of antimicrobial resistance in hospitals. Infect Control Hosp Epidemiol 1997; 18: 275-91.
24. Boyce JM. Understanding and controlling methicillin-resistant Staphylococcus aureus infections. Infect Control Hosp Epidemiol 2002; 23: 485-7.
25. Fukatsu K, Saito HK, Matsuda T. Influences of type and duration of antimicrobial prophylaxis on an outbreak of methicillin-resistant Staphylococcus aureus and on the incidence of wound infection. Arch Surg 1997; 132: 1320-5.
26. Landman D, Chockalingam M, Quale JM. Reduction in the incidence of methicillin-resistant Staphylococcus aureus and ceftazidime-resistant Klebsiella pneumoniae following changes in a hospital antibiotic formulary. Clin Infect Dis 1999; 28: 1062-6.
27. Gruson D, Hilbert G, Vargas F et al. Rotation and restricted use of antibiotics in a medical intensive care unit: Impact on the incidence of ventilator-associated pneumonia caused by antibiotic-resistant Gram-negative bacteria. Am J Respir Crit Care Med 2000; 162: 837-43.
28. Frank MO, Batteiger BE, Sorenson SJ et al. Decrease in expenditures and selected nosocomial infections following implementation of an antimicrobial-prescribing improvement programme. Clin Perform Qual Health Care 1997; 5: 180-8.
29. Geissler A, Gerbeaux P, Granier I et al. Rational use of antibiotics in the intensive care unit: Impact on microbial resistance and costs. Intensive Care Med 2003; 29: 49-54.
30. Smith DW. Decreased antimicrobial resistance after changes in antibiotic use. Pharmacotherapy 1999; 19 Suppl 8: 129-32.
31. Crowcroft NS, Ronveaux O, Monnet DL et al. Methicillin-resistant Staphylococcus aureus and antimicrobial use in Belgian hospitals. Infect Control Hosp Epidemiol 1999; 20: 31-6.
32. Washio M, Mizoue T, Kajioka T et al. Risk factors for methicillin-resistant Staphylococcus aureus (MRSA) infection in a Japanese geriatric hospital. Public Health 1997; 111: 187-90.
33. Khan OA, Weston VC, Scammell BE. Methicillin-resistant Staphylococcus aureus incidence and outcome in patients with neck of femur fractures. J Hosp Infect 2002; 51: 185-8.
34. Muller AA, Mauny F, Bertin M et al. Relationship between spread of methicillin-resistant Staphylococcus aureus and antimicrobial use in a French university hospital. Clin Infect Dis 2003; 36: 971-8.
35. Grundmann H. Methicillin-resistant Staphylococcus aureus in a teaching hospital: Investigation of nosocomial transmission using a matched case-control study. Dissertation. London School for Tropical Medicine and Hygiene, 1997.
36. Monnet DL. Methicillin-resistant Staphylococcus aureus and its relationship to antimicrobial use: Possible implications for control. Infect Control Hosp Epidemiol 1998; 19: 552-9.
37. Dziekan G, Hahn A, Thune K et al. Methicillin-resistant Staphylococcus aureus in a teaching hospital: Investigation of nosocomial transmission using a matched case-control study. J Hosp Infect 2000; 46: 263-70.
38. Harbath S, Harris AD, Carmeli Y et al. Parallel analysis of individual and aggregated data on antibiotic exposure and resistance in Gram-negative bacilli. Clin Infect Dis 2001; 33: 1462-8.
39. Hori S, Sunley R, Tami A et al. The Nottingham Staphylococcus aureus population study: Prevalence of MRSA among elderly in a university hospital. J Hosp Infect 2002; 50: 19-25.
40. Campillo B, Dupeyron C, Richardet JP. Epidemiology of hospital-acquired infections in cirrhotic patients: Effect of carriage of methicillin-resistant Staphylococcus aureus and influence of previous antibiotic therapy and norfloxacin prophylaxis. Epidemiol Infect 2001; 127: 443-50.
41. Drinka PJ, Stemper ME, Gauerke CD et al. Is methicillin-resistant Staphylococcus aureus more contagious than methicillin-susceptible S. aureus in a surgical intensive care unit? Infect Control Hosp Epidemiol 2004; 25: 363-4.
42. Harbath S, Liassine N, Dharan S et al. Risk factors for persistent carriage of methicillin-resistant Staphylococcus aureus. Clin Infect Dis 2000; 31: 1380-5.
43. Schneider-Lindner V, Delaney JA, Dial S et al. Antimicrobial drugs and community-acquired methicillin-resistant Staphylococcus aureus United Kingdom. Emerg Infect Dis 2007; 13: 994-1000.
44. Muto CA, Jernigan JA, Ostrowsky BE et al. SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of Staphylococcus aureus and Enterococcus. Infect Control Hosp Epidemiol 2003; 24: 362-86.
45. Knudsen AM, Rosdahl VT. The decline of methicillin resistance among Danish Staphylococcus aureus strains. Infect Control Hosp Epidemiol 1991; 12: 83-8.
46. Ayliffe GAJ, Lilly HA, Lowbury EJL. Decline of the hospital Staphylococcus? Incidence of multiresistant Staph. aureus in three Birmingham hospitals. Lancet 1979; 313: 538-41.
47. Hoiby N, Jarlov JO, Kemp M et al. Excretion of ciprofloxacin in sweat and multiresistant Staphylococcus epidermidis. Lancet 1997; 349: 167-9.
48. Oppenheim BA, Hartley JW, Lee W et al. Outbreak of coagulase negative Staphylococcus highly resistant to ciprofloxacin in a leukaemia unit. BMJ 1989; 299: 294-7.
49. Chang S, Sievert D, Hageman JC et al. Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene. N Engl J Med 2003; 348: 1342-7.
50. Clark NC, Weigel LM, Patel JB et al. Comparison of Tn 1546 like elements in vancomycin-resistant Staphylococcus aureus isolates from Michigan and Pennsylvania. Antimicrob Agents Chemother 2005; 49: 470-2.
51. Hiramatsu K, Hanaki H, Ino T et al. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997; 40: 135-46.
52. Tenover FC, Biddle JW, Lancaster MV. Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus. Emerg Infect Dis 2001; 7: 327-32.
53. Cartolano GL, Cheron M, Benabid D et al. Methicillin-resistant Staphylococcus aureus (MRSA) with reduced susceptibility to glycopeptides (GISA) in 63 French general hospitals. Clin Microbiol Infect 2004; 10: 448-51.
54. Nonhoff C, Denis O, Struelens MJ. Low prevalence of methicillin-resistant Staphylococcus aureus with reduced susceptibility to glycopeptides in Belgian hospitals. Clin Microbiol Infect 2005; 11: 214-20.
55. Aucken HM, Ganner M, Murchan S et al. A new UK strain of epidemic methicillin-resistant Staphylococcus aureus (EMRSA-17) resistant to multiple antibiotics. J Antimicrob Chemother 2002; 50: 171-5.
56. Bertrand X, Hocquet D, Thouverez M et al. Characterisation of methicillin-resistant Staphylococcus aureus with reduced susceptibility to teicoplanin in Eastern France. Clin Microbiol Infect 2003; 22: 504-6.
57. Drew RH, Perfect JR, Srinath L et al. Treatment of methicillin-resistant Staphylococcus aureus infections with quinupristin-dalfopristin in patients intolerant of or failing prior therapy. J Antimicrob Chemother 2002; 46: 775-84.
58. Moise PA, Schentag JJ. Vancomycin treatment failures in Staphylococcus aureus lower respiratory tract infections. Int J Antimicrob Agents 2000; 16 Suppl 1: S31-4.
59. Sander A, Beiderlinden M, Schmid EN et al. Clinical experience with quinupristin-dalfopristin as rescue treatment of critically ill patients infected with methicillin-resistant staphylococci. Intensive Care Med 2002; 28: 1157-60.
60. Sakoulas G, Moise-Broder PA, Schentag JJ et al. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteraemia. J Clin Microbiol 2004; 42: 2398-402.
61. Moise-Broder PA, Sakoulas G, Eliopoulos GM et al. Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Clin Infect Dis 2004; 38: 1700-5.
62. Maclayton DO, Suda KJ, Coval KA et al. Case-control study of the relationship between MRSA bacteremia with a vancomycin MIC of 2 μg/mL and risk factors, costs, and outcomes in inpatients undergoing hemodialysis. Clin Ther 2006; 28: 1208-16.
63. Hidayat LK, Hsu DI, Quist R et al. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med 2006; 166: 2138-44.
64. Fowler VG Jr, Boucher HW, Corey GR et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006; 355: 653-65.
65. Wysocki M, Delatour F, Faurisson F et al. Continuous versus intermittent infusion of vancomycin in severe staphylococcal infections: prospective multicenter randomized study. Antimicrob Agents Chemother 2001; 45: 2460-7.
66. Jeffres MN, Isakow W, Doherty JA et al. Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia: Specific evaluation of vancomycin pharmacokinetic indices. Chest 2006; 130: 947-55.
67. Jeffres MN, Isakow W, Doherty JA et al. A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia. Clin Ther 2007; 29: 1107-15.
68. Soriano A, Marco F, Martinez JA et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008; 46: 193-200.
69. Tenover FC, Moellering RC Jr The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin Infect Dis 2007; 44: 1208-15.
70. Cosgrove S, Sakoulas G, Peremcevitch EN et al. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteraemia: A meta-analysis. Clin Infect Dis 2003; 36: 53-9.
71. Reed SD, Friedman JY, Engemann JJ et al. Costs and outcomes among hemodialysis-dependent patients with methicillin-resistant or methicillin-susceptible Staphylococcus aureus bacteremia. Infect Control Hosp Epidemiol 2005; 26: 175-83.
72. Blot SI, Vandewoude KH, Hoste EA et al. Outcome and attributable mortality in critically ill patients with bacteraemia involving methicillin-susceptible and methicillin-resistant Staphylococcus aureus. Arch Intern Med 2002; 162: 2229-35.
73. Harbath S, Rutschmann O, Sudre P et al. Impact of methicillin resistance on the outcome of patients with bacteraemia caused by Staphylococcus aureus. Arch Intern Med 1998; 158: 182-9.
74. Engemann JJ, Carmeli Y, Cosgrove S et al. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin Infect Dis 2003; 36: 592-8.
75. Melzer M, Eykyn SJ, Chinn S. Is methicillin-resistant Staphylococcus aureus more virulent than methicillin-susceptible S. aureus? A comparative cohort study of British patients with nosocomial infection and bacteraemia. Clin Infect Dis 2003; 37: 1453-60.
76. Romero-Vivas J, Rubio J, Fernandez C et al. Mortality associated with nosocomial bacteraemia due to methicillin-resistant Staphylococcus aureus. Clin Infect Dis 1995; 21: 1417-23.
77. Stamm AM, Long MN, Belcher B. Higher overall nosocomial infection rate because of increased attack rate of methicillin-resistant Staphylococcus aureus. Am J Infect Control 1993; 21: 70-4.
78. Bader MS. Staphylococcus aureus bacteremia in older adults: predictors of 7-day mortality and infection with a methicillin-resistant strain. Infect Control Hosp Epidemiol 2006; 27: 1219-25.
79. Wyllie DH, Crook DW, Peto TE. Mortality after Staphylococcus aureus bacteraemia in two hospitals in Oxfordshire, 1997-2003: Cohort study. BMJ 2006; 333: 281.
80. Kim S-H, Park W-B, Lee K-D et al. Outcome of inappropriate initial antimicrobial treatment in patients with methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother 2004; 54: 489-97.
81. Lodise TP, MacKinnon PS, Swiderski L et al. Outcomes analysis of delayed antibiotic treatment for hospital-acquired Staphylococcus aureus bacteraemia. Clin Infect Dis 2003; 36: 1418-23.
82. French G. Review of new guidelines for prophylaxis and treatment of MRSA infections. Br J Hosp Med (Lond) 2006; 67: 482-6.
83. Gonzalez C, Rubio M, Romero-Vivas J et al. Bacteremic pneumonia due to Staphylococcus aureus: A comparison of disease caused by methicillin-resistant and methicillin-susceptible organisms. Clin Infect Dis 2003; 29: 1171-7.
84. Mylotte JM, Tayara A. Staphylococcus aureus bacteraemia: predictors of 30-day mortality in a large cohort. Clin Infect Dis 2000; 31: 1170-4.
85. Jensen AG, Wachmann CH, Espersen F et al. Treatment and outcome of Staphylococcus aureus bacteraemia: A prospective study of 278 cases. Ann Intern Med 2002; 162: 25-32.
86. Chang F-Y, Peacock JE, Musher DM et al. Staphylococcus aureus bacteraemia: Recurrence and the impact of antibiotic treatment in a prospective multicenter study. Medicine 2003; 82: 333-9.
87. Fowler VG, Justica A, Moore C et al. Risk factors for hematogenous complications of intravascular catheter-associated Staphylococcus aureus bacteraemia. Clin Infect Dis 2005; 40: 695-703.
88. Johnson LB, Almoujahed MO, Ilg K et al. Staphylococcus aureus bacteremia: Compliance with standard treatment, long-term outcome and predictors of relapse. Scand J Infect Dis 2003; 35: 782-9.
89. Hope R, Livermore DM, Brick G et al. Non-susceptibility trends among staphylococci from bacteraemias in the UK and Ireland, 2001-06. J Antimicrob Chemother 2008; 62 Suppl 2: Ii65-74.
90. Gordts B, Firre E, Legrand J-C et al. National guidelines for the judicious use of glycopeptides in Belgium. Clin Microbiol Infect 2000; 6: 585-92.
91. Koning S, Verhagen A, van Suijlekom-Smit L et al. Interventions for impetigo. Cochrane Database Syst Rev 2003; issue 2: CD003261.
92. Lee MC, Rios AM, Ten MF. Management and outcome of children with skin and soft tissue abscesses caused by community-acquired methicillin-resistant Staphylococcus aureus. Pediatr Infect Dis J 2004; 23: 123-7.
93. Yang LP, Keam SJ. Retapamulin: A review of its use in the management of impetigo and other uncomplicated superficial skin infections. Drugs 2008; 68: 855-73.
94. Rajendran PM, Young D, Maurer T et al. Treatment of abscesses in the era of methicillin resistant Staphylococcus aureus-are antibiotics necessary? J Am Coll Surg 2006; 203: S59.
95. Cenizal MJ, Skiest D, Luber S et al. Prospective randomized trial of empiric therapy with trimethoprim-sulfamethoxazole or doxycycline for outpatient skin and soft tissue infections in an area of high prevalence of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2007; 51: 2628-30.
96. Weigelt J, Itani K, Stevens D et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2005; 49: 2260-6.
97. Itani K, Weigelt J, Stevens D et al. Efficacy and safety of linezolid versus vancomycin for the treatment of complicated skin and soft-tissue infections proven to be due to meticillin-resistant Staphylococcus aureus. In: Abstracts of the Eighteenth European Congress of Clinical Microbiology and Infectious Diseases, Barcelona, Spain, 2008. Abstract O80. http://www.blackwellpublishing.com/ eccmid18/abstract.asp?id=68123 (23 December 2008, date last accessed).
98. Tice A, Rehm SJ, Dalovisio J et al. Practice guidelines for parenteral antibiotic therapy. Clin Infect Dis 2004; 38: 1651-72.
99. Arbeit RD, Maki D, Tally FP et al. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004; 38: 1673-81.
100. Postier RG et al. Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients. Clin Ther 2004; 26: 704-14.
101. Stevens DL, Ma YS, Salmi DB et al. Impact of antibiotics on expression of virulence-associated exotoxin genes in methicillin-sensitive and methicillin-resistant Staphylococcus aureus. J Infect Dis 2007; 195: 202-11.
102. Cox RA, Conquest C, Mallaghan C et al. A major outbreak of methicillin-resistant Staphylococcus aureus caused by a new phage-type (EMRSA-16). J Hosp Infect 1995; 29: 87-106.
103. Falagas ME, Siempos II, Vardakas KZ. Linezolid versus glycopeptide or Β-lactam for treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials. Lancet Infect Dis 2008; 8: 53-66.
104. Wagenlehner FM, Lehn N, Witte W et al. In vitro activity of daptomycin versus linezolid and vancomycin against Gram-positive uropathogens and ampicillin against enterococci, causing complicated urinary tract infections. Chemotherapy 2005; 51: 64-9.
105. Naber KG. Daptomycin versus ciprofloxacin in the treatment of complicated urinary tract infection due to Gram positive bacteria. Infect Dis Clin Practice 2004; 12: 322-7.
106. Tally FP, Zeckel M, Wasilewski MM. Daptomycin: A novel agent for Gram-positive infections. Expert Opin Investig Drugs 1999; 8 1223-38.
107. Stein GE, Craig WA. Tigecycline: A critical analysis. Clin Infect Dis 2006; 43: 518-24.
108. Bergeron MG, Montay G. The pharmacokinetics of quinupristin/dalfopristin in laboratory animals and in humans. J Antimicrob Chemother 1997; 39 Suppl A: 129-38.
109. Falagas ME, Giannopoulou F, Ntziora F et al. Daptomycin for treatment of patients with bone and joint infections: A systematic review of the clinical evidence. Int J Antimicrob Agents 2007; 30: 202-9.
110. Rouse MS, Piper KE, Jacobson M et al. Daptomycin treatment of Staphylococcus aureus experimental chronic osteomyelitis. J Antimicrob Chemother 2006; 57: 301-5.
111. Hall EW, Rouse MS, Jacofsky DJ et al. Release of daptomycin from polymethylmethacrylate beads in a continuous flow chamber. Diagn Microbiol Infect Dis 2004; 50: 261-5.
112. Kandemir O, Oztuna V, Colak M et al. Comparison of the efficacy of tigecycline and teicoplanin in an experimental methicillin-resistant Staphylococcus aureus osteomyelitis model. J Chemother 2008; 20: 53-7.
113. Yin LY, Lazzarini L, Li F et al. Comparative evaluation of tigecycline and vancomycin, with and without rifampicin, in the treatment of methicillin-resistant Staphylococcus aureus experimental osteomyelitis in a rabbit model. J Antimicrob Chemother 2005; 55: 995-1002.
114. Rao N, Hamilton CW. Efficacy and safety of linezolid for Gram-positive orthopaedic infections: A prospective case series. Diagn Microbiol Infect Dis 2007; 59: 173-9.
115. Senneville E, Legout L, Valette M et al. Effectiveness and tolerability of prolonged linezolid treatment for chronic osteomyelitis: a retrospective study. Clin Ther 2006; 28: 1155-63.
116. Bassetti M, Vitale F, Melica G et al. Linezolid in the treatment of Gram-positive prosthetic joint infections. J Antimicrob Chemother 2005; 55: 387-90.
117. Levine DP, Lamp KC. Daptomycin in the treatment of patients with infective endocarditis: Experience from a registry. Am J Med 2007; 120: S28-33.
118. Martone WJ, Katz D. Community-phenotype methicillin resistant Staphylococcus aureus infections: Experience in the 2005 Cubicin Outcomes Registry and Experience (CORE2005). In: Abstracts of the Forty-fourth IDSA Annual Meeting, Toronto, Canada, 2006. Abstract 382, p. 118. Infectious Diseases Society of America, Arlington, VA, USA.
119. Toh S, Xiang L, Arias CA et al. Acquisition of a natural resistance gene renders a clinical strain of methicillin-resistant Staphylococcus aureus resistant to the synthetic antibiotic linezolid. Mol Microbiol 2007; 64: 1506-14.
120. Kelly S, Collins J, Maguire M et al. An outbreak of colonisation with linezolid-resistant Staphylococcus epidermidis in an intensive therapy unit. J Antimicrob Chemother 2008; 61: 901-7.
121. Kainer MA, Devasia RA, Jones TF et al. Response to emerging infection leading to outbreak of linezolid-resistant enterococci. Emerg Infect Dis 2007; 13: 1024-30.
122. Dobbs T, Patel M, Waites KB et al. Nosocomial spread of Enterococcus faecium resistant to vancomycin and linezolid in a tertiary medical center. J Clin Microbiol 2006; 44: 3368-70.
123. Bonora M, Solbiati M, Stepan E et al. Emergence of linezolid resistance in the vancomycin-resistant Enterococcus faecium multilocus sequence typing C1 epidemic lineage. J Clin Microbiol 2006; 44: 1153-5.
124. Silverman J, Mortin LI, Vanpraagh A et al. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis 2005; 191: 2149-52.
125. Ntziora F, Falagas ME. Linezolid for the treatment of patients with central nervous system infection. Ann Pharmacother 2007; 41: 296-308.
126. Gerber P, Stucki A, Acosta F et al. Daptomycin is more efficacious than vancomycin against a methicillin-susceptible Staphylococcus aureus in experimental meningitis. J Antimicrob Chemother 2006; 57: 720-3.
127. Maraha B, van Halteren J, Verzijt JM et al. Decolonization of methicillin-resistant Staphylococcus aureus using oral vancomycin and topical mupirocin. Clin Microbiol Infect 2002; 8: 671-5.
128. Perez-Roth E, Lopez-Aguilar C, Alcob-Florez J et al. High-level mupirocin resistance within methicillin-resistant Staphylococcus aureus pandemic lineages. Antimicrob Agents Chemother 2006; 50: 3207-11.
129. Vivoni AM, Santos KR, de Oliveira MP et al. Mupirocin for controlling methicillin-resistant Staphylococcus aureus: Lessons from a decade of use at a university hospital. Infect Control Hosp Epidemiol 2005; 26: 662-7.
130. Silvestri L, van Saene HK, Milanese M. Prevention of MRSA pneumonia by oral vancomycin decontamination: A randomised trial. Eur Respir J 2004; 23: 921-9.
131. de la Cal MA, Cerda E, van Saene HK et al. Effectiveness and safety of enteral vancomycin to control endemicity of methicillin-resistant Staphylococcus aureus in a medical/surgical intensive care unit. J Hosp Infect 2004; 56: 175-83.
132. Silvestri L, Milanese M, Oblach L et al. Enteral vancomycin to control methicillin-resistant Staphylococcus aureus outbreak in mechanically ventilated patients. Am J Infect Control 2002; 30 391-9.